(TheNewswire)
25-Year Industry Veteran inClinical/Regulatory Therapeutics Development
Joins Sernova’s ExecutiveTeam
L ondon, Ontario - TheNewswire - June 30, 2021– Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH ), aleading clinical-stage regenerative medicine therapeutics company,today announced that pharmaceutical industry executive, Frank Shannonhas joined Sernova as Vice President, Clinical Development andRegulatory Affairs.
"In his distinguished career focused on NorthAmerican and International clinical development and regulatory affairsof therapeutic products, Mr. Shannon has developed extensive knowledgeand experience in a number of therapeutic areas,” said Dr. PhilipToleikis, President & CEO Sernova Corp. “Importantly, he hasworked in both smaller emerging biopharma companies as well as withinternational pharmaceutical conglomerates and his experience in theexecution of combination product clinical development will beinvaluable for Sernova’s novel cell therapy developmentprograms.”
Dr. Toleikis continued, "With Sernova’s clinicalsuccess to date in type 1 diabetes (T1D), we look forward toleveraging Mr. Shannon’s strategic expertise to further progress ourongoing T1D program, including our current US Phase I/II Cell Pouch™clinical trial, and our local immune protection and stem celltechnology initiatives as well as driving clinical development of ourother therapeutic programs in thyroid disease and hemophiliaA.”
Mr. Shannon has a track record of more than 25 years ofproven experience in clinical development and regulatory affairs. Hehas served in senior level positions within the international medicaldevice, pharmaceutical, and biologic industries where he achievedcommercial goals through innovative risk management and executionstrategies, to obtain marketing approval of products.
Mr. Shannon most recently served as VP ClinicalDevelopment, Regulatory Affairs and Quality at Ripple Therapeutics, aspin-out of Interface Biologics where he served in the same capacitysince 2006. Prior to these appointments, he held various seniorclinical/regulatory positions at Baxter International, St. JudeMedical, Boehringer-Ingelheim, Hoffmann-La Roche/Roche Laboratories,Inc., Genentech Canada, Inc., and Ciba-Geigy Canada, Ltd.
"I am thrilled to be joining Sernova at such anexciting time in its development,” said Frank Shannon. “I lookforward to bringing the learnings from all of my experiences topositively impact Sernova’s expanding clinical programs as thecompany advances its novel leading regenerative medicine therapeuticprograms."
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologiesusing its Cell Pouch medical device, therapeutic cells (i.e., humandonor cells, corrected human cells, stem cell-derived cells andtissues) and immune protection technologies to improve the treatmentand quality of life of people living with chronic metabolic diseasessuch as insulin-dependent diabetes, blood disorders includinghemophilia, and other diseases treated through replacement of proteinsor hormones missing or in short supply within the body. For moreinformation, please visit www.sernova.com .
FOR FURTHER INFORMATION, PLEASECONTACT:
Investor Relations
Sernova Corp.
Tel: (519) 858-5126
investorrelations@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extentthey are not recitations of historical facts, may constitute“forward-looking statements” that involve various risks,uncertainties, and assumptions, including, without limitation,statements regarding the prospects, plans, and objectives of thecompany. Wherever possible, but not always, words such as"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential for" and similarexpressions, or that events or conditions "will","would", "may", "could" or"should" occur are used to identify forward-lookingstatements. These statements reflect management’s beliefs withrespect to future events, including results of clinical trials, andare based on information currently available to management on the datesuch statements were made. Many factors could cause Sernova’s actualresults, performances or achievements to not be as anticipated,estimated or intended or to differ materially from those expressed orimplied by the forward-looking statements contained in this newsrelease. Many of the factors are beyond our control, including thosecaused by, related to, or impacted by the novel coronavirus pandemic.Investors should consult the company’s quarterly and annual filingsavailable on www.sedar.com for additional information on risks anduncertainties relating to the forward-looking statements. Sernovaexpressly disclaims any intention or obligation to update or reviseany forward-looking statements, whether as a result of newinformation, future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.